{"id":1019544,"date":"2026-11-10T11:40:05","date_gmt":"2026-11-10T16:40:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\/"},"modified":"2026-11-10T11:40:05","modified_gmt":"2026-11-10T16:40:05","slug":"alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\/","title":{"rendered":"Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD"},"content":{"rendered":"

<\/p>\n

Alnylam Collaborator Regeneron Advances CIDEBsiRNA<\/sup> with Promising First-in-Human Results in Patients with MASLD<\/b><\/p>\n

Single administration of CIDEBsiRNA<\/sup> resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks<\/i><\/p>\n

Data shared in oral presentation at AASLD The Liver Meeting\u00ae<\/sup> and simultaneously published in The New England Journal of Medicine<\/i><\/p>\n

Results demonstrate how Alnylam’s RNAi platform and strategic partnerships can expand therapeutic opportunities and create long-term value beyond its wholly owned pipeline<\/i><\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–Alnylam Pharmaceuticals, Inc.<\/a> (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its collaborator, Regeneron Pharmaceuticals, Inc. shared initial results from a first-in-human trial that demonstrated a single subcutaneous dose of CIDEBsiRNA<\/sup> (previously known as ALN-CIDEB) rapidly normalized liver fat and improved liver injury markers in patients with metabolic-dysfunction-associated steatotic liver disease (MASLD) with effects that were sustained through week 36. The Regeneron data were published by The New England Journal of Medicine <\/i>and simultaneously presented in an oral session at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting\u00ae<\/sup> 2026.<\/p>\n

\nCIDEBsiRNA<\/sup> is an investigational RNAi therapeutic (also known as an siRNA therapeutic). Scientists at the Regeneron Genetics Center\u00ae<\/sup> (RGC) analyzed genetic data to discover and\/or validate genetic variants in the CIDEB and other genes that are associated with liver disease risk. Building on these findings, Regeneron collaborated with Alnylam to generate an siRNA targeting CIDEB. Since 2023 when the candidate was identified, Regeneron has led development and holds exclusive rights for commercialization of CIDEBsiRNA<\/sup>. Alnylam is eligible to receive development milestones and tiered, double-digit royalties up to 20%.<\/p>\n

\n\u201cThe magnitude and durability of the reductions in liver fat observed with CIDEBsiRNA<\/sup> following a single administration are particularly encouraging and represent an important early signal for the potential of RNAi in treating metabolic liver disease,\u201d said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. \u201cThese findings reinforce our conviction that RNAi therapeutics can address a much broader range of diseases than those we treat today. They also demonstrate the value of our partnership model, which allows promising science to advance into new disease areas, reach more patients and create additional opportunities for long-term value.\u201d<\/p>\n

\nRegeneron\u2019s ongoing Phase 1\/2 randomized, double-blind, placebo-controlled trial is evaluating the safety and tolerability of CIDEBsiRNA<\/sup> in adult participants with MASLD and metabolic dysfunction-associated steatohepatitis (MASH). The primary goal of the trial is to evaluate safety and tolerability with efficacy evaluated as a secondary endpoint through measures such as change in liver fat fraction by magnetic resonance imaging-proton density fat fraction (MRI-PDFF).<\/p>\n

About RNAi
\n
<\/b>RNAi (RNA interference) is a natural cellular process of gene silencing that has become an important and clinically validated platform for drug development. Its discovery was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing RNAi, Alnylam pioneered a new class of medicines known as RNAi therapeutics. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam\u2019s therapeutic platform, function upstream of today\u2019s medicines by potently silencing messenger RNA (mRNA) \u2013 the genetic precursors \u2013 that encode for disease-causing or disease pathway proteins, thus preventing them from being made. RNAi therapeutics have been used to treat hundreds of thousands of patients worldwide, demonstrating the impact of this approach across rare and common diseases.<\/p>\n

About Alnylam Pharmaceuticals
\n
<\/b>Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. For more information, please visit www.alnylam.com<\/a> or follow Alnylam on X<\/a>, LinkedIn<\/a>, Facebook<\/a>, Instagram<\/a>, or YouTube<\/a>.<\/p>\n

Forward-Looking Statements
\n
<\/b>This press release contains forward-looking statements. Forward-looking statements include statements regarding Alnylam\u2019s expectations, beliefs, goals, plans or prospects, including, without limitation, statements regarding: the potential efficacy or safety of CIDEBsiRNA<\/sup> for the treatment of MASLD or any other indication; the potential for Alnylam to receive milestones or royalties on account of the development and\/or commercialization of CIDEBsiRNA<\/sup>; the potential for RNAi to treat metabolic liver disease and to address a much broader range of diseases than those treated today; the potential for Alnylam\u2019s partnership model to allow Alnylam to allow promising science to advance into new disease areas, reach more patients and create additional opportunities for long-term value; and Alnylam\u2019s ability to achieve the goals in its Alnylam<\/i>2030 <\/i>strategy. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam\u2019s ability to successfully execute on its Alnylam 2030<\/i> strategy; Alnylam\u2019s ability to successfully launch, market and sell Alnylam\u2019s approved products globally; Alnylam\u2019s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam\u2019s product candidates; actions or advice of regulatory agencies and Alnylam\u2019s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; delays, interruptions or failures in the manufacture and supply of Alnylam\u2019s marketed products or its product candidates; obtaining, maintaining and protecting intellectual property; Alnylam\u2019s ability to manage its growth and operating expenses through disciplined investment in operations; Alnylam\u2019s ability to maintain strategic business collaborations; Alnylam\u2019s dependence on third parties for the development and commercialization of certain products; the outcome of litigation and government investigations; the risk of future litigation and government investigations; and unexpected expenditures; as well as those risks and uncertainties more fully discussed in the \u201cRisk Factors\u201d filed with Alnylam\u2019s most recent periodic report (Quarterly Report on Form 10-Q or Annual Report on Form 10-K) filed with the SEC and in its other SEC filings. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20261110694883\/en\/<\/a><\/span><\/p>\n

\nAlyssa Kneller
\n
(Media)
\n
media@alnylam.com
\n<\/a><\/p>\n

Josh Brodsky
\n
(Investors)
\n
investors@alnylam.com<\/a><\/p>\n

KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD Single administration of CIDEBsiRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks Data shared in oral presentation at AASLD The Liver Meeting\u00ae and simultaneously published in The New England Journal of Medicine Results demonstrate how Alnylam’s RNAi platform and strategic partnerships can expand therapeutic opportunities and create long-term value beyond its wholly owned pipeline CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its collaborator, Regeneron Pharmaceuticals, Inc. shared initial results from a first-in-human trial that demonstrated a single subcutaneous dose of CIDEBsiRNA (previously known as ALN-CIDEB) rapidly normalized … <\/p>\n

Continue reading “Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1019544","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAlnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD Single administration of CIDEBsiRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks Data shared in oral presentation at AASLD The Liver Meeting\u00ae and simultaneously published in The New England Journal of Medicine Results demonstrate how Alnylam’s RNAi platform and strategic partnerships can expand therapeutic opportunities and create long-term value beyond its wholly owned pipeline CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its collaborator, Regeneron Pharmaceuticals, Inc. shared initial results from a first-in-human trial that demonstrated a single subcutaneous dose of CIDEBsiRNA (previously known as ALN-CIDEB) rapidly normalized … Continue reading "Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-10T16:40:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261110694883r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD\",\"datePublished\":\"2026-11-10T16:40:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\\\/\"},\"wordCount\":1105,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261110694883r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\\\/\",\"name\":\"Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261110694883r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-11-10T16:40:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261110694883r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261110694883r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\/","og_locale":"en_US","og_type":"article","og_title":"Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD - Market Newsdesk","og_description":"Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD Single administration of CIDEBsiRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks Data shared in oral presentation at AASLD The Liver Meeting\u00ae and simultaneously published in The New England Journal of Medicine Results demonstrate how Alnylam’s RNAi platform and strategic partnerships can expand therapeutic opportunities and create long-term value beyond its wholly owned pipeline CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its collaborator, Regeneron Pharmaceuticals, Inc. shared initial results from a first-in-human trial that demonstrated a single subcutaneous dose of CIDEBsiRNA (previously known as ALN-CIDEB) rapidly normalized … Continue reading \"Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-10T16:40:05+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261110694883r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD","datePublished":"2026-11-10T16:40:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\/"},"wordCount":1105,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261110694883r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\/","name":"Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261110694883r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-11-10T16:40:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261110694883r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261110694883r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-collaborator-regeneron-advances-cidebsirna-with-promising-first-in-human-results-in-patients-with-masld\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1019544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1019544"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1019544\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1019544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1019544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1019544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}